MAP2K1 and colorectal carcinoma: In addition, the ongoing phase I/II MErCuRIC clinical trial of combined c-MET/MEK1/2 inhibition in RASMT and RASWT metastatic CRC with aberrant c-MET expression, is assessing MET RNA ISH, IHC and DDISH in CRC liver metastasis and its potential as predictive biomarker [58].